Boston Scientific Begins Marketing Remote Catheter System in Europe Through Exclusive Agreement With Catheter Robotics

Paris, November 15 (ots/PRNewswire) -

CRI's Amigo(TM) system allows remote control of Boston
Scientific's leading cardiac ablation catheters

Boston Scientific Corporation is beginning to market the CRI
Amigo(TM) system, a remote-controlled catheter system, and related
accessories in select European countries through an exclusive
agreement with Catheter Robotics, Inc. (CRI). The CRI Amigo(TM)
system, compatible with certain Boston Scientific and other
commercially available catheters, lets physicians remotely maneuver
diagnostic and ablation catheters designed to treat common cardiac
arrhythmias during electrophysiology procedures. Boston Scientific
plans to market the Amigo system in Austria, Belgium, France,
Germany, Luxembourg, The Netherlands, Portugal, Spain and
Switzerland.

"To perform successful ablation procedures, electrophysiologists
require precise control over catheter tip placement," said Jean Paul
Albenque, M.D., Clinique Pasteur, Toulouse, France. "The Amigo Remote
Catheter System, used in combination with the predictable steering
and stability of Boston Scientific's leading RF ablation catheters,
offers improved comfort and reduced radiation exposure without
sacrificing performance."

The Amigo system is designed to integrate easily into existing
catheter labs for use in simple and complex procedures to diagnose
and treat cardiac arrhythmias. It connects to the handle of specific
electrophysiological catheters and lets the physician remotely
operate the catheter with a controller. The system is intended to
allow full operation of all catheter functions while reducing a
physician's radiation exposure during the procedure.

The Amigo system is compatible with Boston Scientific's
Blazer(TM) and Blazer(TM) Open-Irrigated radiofrequency (RF) ablation
catheters and Chilli II(R) fluid cooled RF ablation catheter. The
Blazer Open-Irrigated Catheter, launched in CE Mark countries in May
2011, is an advanced catheter that integrates Total Tip Cooling(TM)
Design, which is intended to consistently cool the entire tip
electrode during RF energy delivery.

"The Amigo system complements our leading line of EP catheters,
offering electrophysiologists an intuitive solution for remote
operation while retaining the full functionality of their preferred
ablation catheter platforms," said Michael Onuscheck, Executive Vice
President and President of Boston Scientific EMEA. "This agreement
with Catheter Robotics is an important step in our continued focus on
advancing cardiac ablation solutions for European physicians and
their patients."

Affecting more than 4.5 million Europeans, atrial fibrillation is
an arrhythmia associated with a rapid rhythm in the upper chambers of
the heart. Patients are most often treated with anti-arrhythmic
drugs, which can often cause adverse side effects. Cardiac ablation
with an RF ablation catheter is increasingly becoming an option for
patients who cannot tolerate these medications.

In the U.S., the Blazer Open-Irrigated Catheter is an
investigational device, limited by applicable law to investigational
use only and not available for sale.

About Catheter Robotics, Inc.

Catheter Robotics, Inc. (CRI) is a medical device company focused
on providing physicians comfort and safety while remaining committed
to producing cost-effective, user friendly and technologically
differentiated tools for use in percutaneous catheter procedures. For
more information, please visit: http://www.catheterrobotics.com.

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and
marketer of medical devices whose products are used in a broad range
of interventional medical specialties. For more information, please
visit: http://www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E
of the Securities Exchange Act of 1934. Forward-looking statements
may be identified by words like "anticipate," "expect," "project,"
"believe," "plan," "estimate," "intend" and similar words. These
forward-looking statements are based on our beliefs, assumptions and
estimates using information available to us at the time and are not
intended to be guarantees of future events or performance. These
forward-looking statements include, among other things, statements
regarding our business plans; our RFA catheters; the Amigo Remote
Catheter System; product use, performance and compatibility; and
competitive offerings. If our underlying assumptions turn out to be
incorrect, or if certain risks or uncertainties materialize, actual
results could vary materially from the expectations and projections
expressed or implied by our forward-looking statements. These
factors, in some cases, have affected and in the future (together
with other factors) could affect our ability to implement our
business strategy and may cause actual results to differ materially
from those contemplated by the statements expressed in this press
release. As a result, readers are cautioned not to place undue
reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other
things: future economic, competitive, reimbursement and regulatory
conditions; new product introductions; demographic trends;
intellectual property; litigation; financial market conditions; and
future business decisions made by us and our competitors. All of
these factors are difficult or impossible to predict accurately and
many of them are beyond our control. For a further list and
description of these and other important risks and uncertainties that
may affect our future operations, see Part I, Item 1A - Risk Factors
in our most recent Annual Report on Form 10-K filed with the
Securities and Exchange Commission, which we may update in Part II,
Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have
filed or will file hereafter. We disclaim any intention or obligation
to publicly update or revise any forward-looking statements to
reflect any change in our expectations or in events, conditions or
circumstances on which those expectations may be based, or that may
affect the likelihood that actual results will differ from those
contained in the forward-looking statements. This cautionary
statement is applicable to all forward-looking statements contained
in this document.

ots Originaltext: Boston Scientific Corporation
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Simonetta Balbi, PR and Corporate Communication EMEA,
Balbis@bsci.com, Mobile : +39-3387936422